Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer.
- In the news
Daraxonrasib, a first-in-class pan-RAS inhibitor, shrank tumors in over 30% of patients with advanced RAS-mutant non-small cell lung cancer.
- Why it matters: Effective treatments for RAS-mutant non-small cell lung cancer are limited, and new targeted therapies are urgently needed to improve patient outcomes.
- What they did: Researchers evaluated daraxonrasib in previously treated patients, demonstrating tumor reduction in more than 30%, supporting its potential as a targeted therapy.
- The result: These promising results led to approval for pancreatic cancer and bolster ongoing phase III trials in lung cancer, potentially expanding treatment options.